Education
About Us
Working with TipRanks
Follow Us
Evotec AG (EVO)
NASDAQ:EVO
EVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.85 - $7.98
Previous CloseN/A
Volume32.72K
Average Volume (3M)95.37K
Market Cap
$1.15B
Enterprise Value$1.48B
Total Cash (Recent Filing)€24.84M
Total Debt (Recent Filing)€13.00M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Apr 17, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding355,527,040
10 Day Avg. Volume145,322
30 Day Avg. Volume95,371
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.46
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside139.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Bulls Say, Bears Say
Bulls Say
Cost ManagementThe company continues cutting expenses, which will also be positive for the 4Q results.
EarningsManagement is confident in the Q4 performance based on their current order book outlook and their fixed cost increase in revenue, which is expected to lead to a profit uplift.
Bears Say
Margin PressureMargins improved q/q to ~10% for Q3 but fell ~9% y/y due to clinging recovery costs from last year's cyberattack and higher labor/supplier costs tied to increased JEB business.
Revenue PerformanceUnderwhelming Q3 revs of €184.9M driven by shared R&D still seeing macro headwinds.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.37% Other Institutional Investors
98.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was $2.85 and its highest was $7.98 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is $1.15B.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Apr 17, 2025 which is in 16 days.
How were Evotec AG’s earnings last quarter?
Evotec AG released its earnings results on Nov 06, 2024. The company reported -$0.118 earnings per share for the quarter, missing the consensus estimate of -$0.06 by -$0.058.
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG does not currently pay dividends.
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is >-0.01.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,527,040 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Evotec AG reported an EPS of -$0.118 in its last earnings report, missing expectations of -$0.06. Following the earnings report the stock price went down -15.721%.
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in EVO
---
Evotec AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (139.52% Upside)
$8.00 (139.52% Upside)
Blogger Sentiment
Bullish
EVO Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.3%
Last 30 Days ▼ 14.3%
Last 30 Days ▼ 14.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.72%
12-Months-Change
Fundamentals
Return on Equity
-16.21%
Trailing 12-Months
Asset Growth
-6.92%
Trailing 12-Months
Company Description
Evotec AG
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
---
EVO Company Deck
---
EVO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company undergoing significant transformation to address challenging market conditions and operational inefficiencies. While there are strong partnerships and growth in specific segments like Just-Evotec Biologics, declining revenues in shared R&D and market uncertainties pose challenges. The strategic reset aims to position Evotec for future growth, but immediate impacts are still unfolding.Read More>---
EVO Stock 12 Month Forecast
Average Price Target
$8.00
▲(139.52% Upside)
Technical Analysis
Best Analysts Covering EVO
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-26.77%
reiterated a buy rating 5 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -26.77% per trade.
---